Incyte is a global biopharmaceutical company founded on the premise that investment in strong science and the relentless pursuit of R&D excellence can translate into new solutions that can positively affect patients’ lives.
Incyte proudly adds VGA039 and the VIVID study to its hematology portfolio.
VGA039 is a novel investigational monoclonal antibody in Phase 3 development for von Willebrand disease (VWD), and marks Incyte's expansion into bleeding disorders
